

DAFTAR PUSTAKA

- Abenheim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E. & Aubier, M. 1996. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. *N. Engl. J. Med.*,335: 609-616.
- Adatia, I., Barrow, S., Stratton, P., Miall-Allen, V., Ritter, J. & Haworth, S. 1993. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. *Circulation*,88: 2117-2122.
- Adatia, I. & Haworth, S. G. 1993. Circulating endothelin in children with congenital heart disease. *Heart*,69: 233-236.
- Adatia, I., Kothari, S. S. & Feinstein, J. A. 2010. Pulmonary hypertension associated with congenital heart disease: pulmonary vascular disease: the global perspective. *Chest*,137: 52S-61S.
- Allen, S. W., Chatfield, B. A., Koppenhafer, S. A., Schaffer, M. S., Wolfe, R. R. & Abman, S. H. 1993. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension: association with acute hypoxic pulmonary vasoreactivity. *Am. Rev. Respir. Dis.*,148: 519-522.
- Archer, S. L., Weir, E. K. & Wilkins, M. R. 2010. Basic science of pulmonary arterial hypertension for clinicians new concepts and experimental therapies. *Circulation*,121: 2045-2066.
- Badesch, D. B., Raskob, G. E., Elliott, C. G., Krichman, A. M., Farber, H. W., Frost, A. E., Barst, R. J., Benza, R. L., Liou, T. G. & Turner, M. 2010. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. *Chest*,137: 376-387.
- Baretella, O. & Vanhoutte, P. 2016. Endothelium-Dependent Contractions: Prostacyclin and Endothelin-1, Partners in Crime? *Adv. Pharmacol.*
- Barst, R. 1986. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. *Chest*,89: 497-503.
- Beghetti, M., Black, S. M. & Fineman, J. R. 2005. Endothelin-1 in congenital heart disease. *Pediatr. Res.*,57: 16R-20R.
- Beghetti, M. & Galiè, N. 2009. Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. *J. Am. Coll. Cardiol.*,53: 733-740.
- Bonnet, S., Michelakis, E. D., Porter, C. J., Andrade-Navarro, M. A., Thébaud, B., Bonnet, S., Haromy, A., Harry, G., Moudgil, R. & McMurtry, M. S. 2006. An Abnormal Mitochondrial-Hypoxia Inducible Factor-1 α -Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats Similarities to Human Pulmonary Arterial Hypertension. *Circulation*,113: 2630-2641.
- Bourque, S. L., Davidge, S. T. & Adams, M. A. 2011. The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. *Am. J. Physiol. Regul. Integr. Comp. Physiol.*,300: R1288-R1295.
- Brickner, M. E., Hillis, L. D. & Lange, R. A. 2000. Congenital heart disease in adults. *N. Engl. J. Med.*,342: 256-263.

- Burnstock, G. 1999. Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. *J. Anat.*,194: 335-342.
- Butera, G., Carminati, M., Chessa, M., Youssef, R., Drago, M., Giamberti, A., Pomè, G., Bossone, E. & Frigiola, A. 2006. Percutaneous versus surgical closure of secundum atrial septal defect: comparison of early results and complications. *Am. Heart J.*,151: 228-234.
- Butrous, G., Ghofrani, H. A. & Grimminger, F. 2008. Pulmonary vascular disease in the developing world. *Circulation*,118: 1758-1766.
- Christman, B. W., McPherson, C. D., Newman, J. H., King, G. A., Bernard, G. R., Groves, B. M. & Loyd, J. E. 1992. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. *N. Engl. J. Med.*,327: 70-75.
- D'Alto, M. & Mahadevan, V. S. 2012. Pulmonary arterial hypertension associated with congenital heart disease. *Eur. Respir. Rev.*,21: 328-337.
- Deng, Z., Morse, J. H., Slager, S. L., Cuervo, N., Moore, K. J., Venetos, G., Kalachikov, S., Cayanis, E., Fischer, S. G. & Barst, R. J. 2000. Familial primary pulmonary hypertension (Gene PPH1) is caused by mutations in the bone morphogenetic protein receptor–II gene. *Am. J. Hum. Genet.*,67: 737-744.
- Dickinson, M. G., Bartelds, B., Borgdorff, M. A. & Berger, R. M. 2013. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. *Am. J. Physiol. Lung Cell. Mol. Physiol.*,305: L1-L14.
- Diller, G. -P., Dimopoulos, K., Okonko, D., Li, W., Babu-Narayan, S. V., Broberg, C. S., Johansson, B., Bouzas, B., Mullen, M. J. & Poole-Wilson, P. A. 2005. Exercise intolerance in adult congenital heart disease comparative severity, correlates, and prognostic implication. *Circulation*,112: 828-835.
- Du, Z. -D., Hijazi, Z. M., Kleinman, C. S., Silverman, N. H. & Larntz, K. 2002. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. *J. Am. Coll. Cardiol.*,39: 1836-1844.
- Duffels, M. G., Engelfriet, P. M., Berger, R. M., van Loon, R. L., Hoendermis, E., Vriend, J. W., van der Velde, E. T., Bresser, P. & Mulder, B. J. 2007. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. *Int. J. Cardiol*,120: 198-204.
- Ejim, E., Anisiuba, B., Ike, S. & Essien, I. 2011. Atrial septal defects presenting initially in adulthood: patterns of clinical presentation in enugu, South-East Nigeria. *J. Trop. Med.*,2011.
- Engelfriet, P., Boersma, E., Oechslin, E., Tijssen, J., Gatzoulis, M. A., Thilén, U., Kaemmerer, H., Moons, P., Meijboom, F. & Popelová, J. 2005. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. *Eur. HeartJ.*,26: 2325-2333.

- Engelfriet, P., Meijboom, F., Boersma, E., Tijssen, J. & Mulder, B. 2008. Repaired and open atrial septal defects type II in adulthood: an epidemiological study of a large European cohort. *Int. J. Cardiol.*,126: 379-385.
- Faber, H. & Loscalzo, J. 2004. Mechanism of disease: pulmonary arterial hypertension. *N. Engl. J. Med.*,351: 1655-1665.
- Fischer, G., Stieh, J., Uebing, A., Hoffmann, U., Morf, G. & Kramer, H. 2003. Experience with transcatheter closure of secundum atrial septal defects using the Amplatzer septal occluder: a single centre study in 236 consecutive patients. *Heart*,89: 199-204.
- Galiè, N., Hooper, M. M., Humbert, M., Torbicki, A., Vachiery, J. -L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S. & Gibbs, J. S. 2009. Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur. HeartJ.*,30: 2493-2537.
- Galiè, N., Humbert, M., Vachiery, J. -L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Noordegraaf, A. V. & Beghetti, M. 2015. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur. Heart J.* : ehv317.
- Galiè, N., Manes, A. & Branzi, A. 2003. Prostanoids for pulmonary arterial hypertension. *Am. J. Respir. Med.*,2: 123-137.
- Gambone, L. M., Murray, P. A. & Flavahan, N. A. 1997. Synergistic interaction between endothelium-derived NO and prostacyclin in pulmonary artery: potential role for K⁺ ATP channels. *Br. J. Pharmacol.*,121: 271-279.
- Gerber, J., Voelkel, N., Nies, A., McMurtry, I. & Reeves, J. 1980. Moderation of hypoxic vasoconstriction by infused arachidonic acid: role of PGI₂. *J. Appl. Physiol.*,49: 107-112.
- Ghofrani, H. A., Pepke-Zaba, J., Barbera, J. A., Channick, R., Keogh, A. M., Gomez-Sanchez, M. A., Kneussl, M. & Grimminger, F. 2004. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. *J. Am. Coll. Cardiol.*,43: S68-S72.
- Giaid, A., Yanagisawa, M., Langleben, D., Michel, R. P., Levy, R., Shennib, H., Kimura, S., Masaki, T., Duguid, W. P. & Stewart, D. J. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. *N. Engl. J. Med.*,328: 1732-1739.
- Gorenflo, M., Gross, P., Bodey, A., Schmitz, L., Brockmeier, K., Berger, F., Bein, G. & Lange, P. E. 1995. Plasma endothelin-1 in patients with left-to-right shunt. *Am. Heart J.*,130: 537-542.
- Hassoun, P., Thappa, V., Landman, M. & Fanburg, B. 1992. Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. *Exp. Biol. Med.*,199: 165-170.
- Heath, D. & Edwards, J. E. 1958. The pathology of hypertensive pulmonary vascular disease A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. *Circulation*,18: 533-547.
- Herve, P., Drouet, L., Dosquet, C., Launay, J. -M., Rain, B., Simonneau, G., Caen, J. & Duroux, P. 1990. Primary pulmonary hypertension in a patient

- with a familial platelet storage pool disease: role of serotonin. *Am. J. Med.*,89: 117-120.
- Hirata, Y., Emori, T., Eguchi, S., Kanno, K., Imai, T., Ohta, K. & Marumo, F. 1993. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. *J. Clin. Invest.*,91: 1367.
- Huang, H., Zhang, P., Wang, Z., Tang, F. & Jiang, Z. 2011. Activation of endothelin-1 receptor signaling pathways is associated with neointima formation, neoangiogenesis and irreversible pulmonary artery hypertension in patients with congenital heart disease. *Circulation*,75: 1463-1471.
- Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaici, A., Weitzenblum, E., Cordier, J. -F. & Chabot, F. 2006. Pulmonary arterial hypertension in France: results from a national registry. *Am. J. Respir. Crit. Care Med.*,173: 1023-1030.
- Humbert, M., Sitbon, O. & Simonneau, G. 2004. Treatment of pulmonary arterial hypertension. *N. Engl. J. Med.*,351: 1425-1436.
- Humenberger, M., Rosenhek, R., Gabriel, H., Rader, F., Heger, M., Klaar, U., Binder, T., Probst, P., Heinze, G. & Maurer, G. 2010. Benefit of atrial septal defect closure in adults: impact of age. *Eur. Heart J. :* ehq352.
- Ikemoto, Y., Teraguchi, M., Takaya, J., Nogi, S. & Kobayashi, Y. 1998. Plasma levels of nitric oxide products and endothelin in pulmonary hypertension with congenital heart disease. *Acta Paediatr.*,87: 715-716.
- Kiettisanpipop, P., Lertsapcharorn, P., Chotivittayatarakorn, P. & Poovorawan, Y. 2007. Plasma levels of nitric oxide in children with congenital heart disease and increased pulmonary blood flow. *J. Med. Assoc. Thai.*,90: 2053.
- Komai, H., Adatia, I., Elliott, M., De Leval, M. & Haworth, S. 1993. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. *J. Thorac. Cardiovasc. Surg.*,106: 473-478.
- Komar, M., Podolec, J., Płazak, W., Stepniewski, J., Sobień, B., Tomkiewicz-Pająk, L., Przewłocki, T. & Podolec, P. 2014. Elevated level of plasma endothelin-1 in patients with atrial septal defect. *J. Cardiovasc. Ultrasound*,12: 1.
- Kuijpers, J. M., van der Bom, T., van Riel, A. C., Meijboom, F. J., van Dijk, A. P., Pieper, P. G., Vliegen, H. W., Waskowsky, W. M., Oomen, T. & Zomer, A. C. 2015. Secundum atrial septal defect is associated with reduced survival in adult men. *Eur. Heart J. :* ehv097.
- Kulik, T. J. 2012. Pulmonary blood flow and pulmonary hypertension: Is the pulmonary circulation flowophobic or flowophilic? *Pulm. Circ.*,2: 327-339.
- Lam, C. -F., Peterson, T. E., Croatt, A. J., Nath, K. A. & Katusic, Z. S. 2005. Functional adaptation and remodeling of pulmonary artery in flow-induced pulmonary hypertension. *Am. J. Physiol. Heart Circ. Physiol.*,289: H2334-H2341.

- Lee, S., Wang, W., Lanzillo, J. & Fanburg, B. 1994. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. *Am. J. Physiol. Lung Cell. Mol. Physiol.*,266: L46-L52.
- Li, X., Qiu, J., Pan, M., Zheng, D., Su, Y., Wei, M., Kong, X., Sun, W. & Zhu, J. 2015. Correlation between congenital heart disease complicated with pulmonary artery hypertension and circulating endothelial cells as well as endothelin-1. *Int. J. Clin. Exp. Pathol.*,8: 10743.
- Loukanov, T., Arnold, R., Gross, J., Sebening, C., Klimpel, H., Eichhorn, J., Hoss, K., Ulmer, H. E., Kark, M. & Gorenflo, M. 2008. Endothelin-1 and asymmetric dimethylarginine in children with left-to-right shunt after intracardiac repair. *Clin. Res. Cardiol.*,97: 383-388.
- Lourenço, A. P., Fontoura, D., Henriques-Coelho, T. & Leite-Moreira, A. F. 2012. Current pathophysiological concepts and management of pulmonary hypertension. *Int. J. Cardiol.*,155: 350-361.
- Mair, K., Johansen, A., Wright, A., Wallace, E. & MacLean, M. 2014. Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. *Br. J. Pharmacol.*,171: 567-579.
- Marelli, A. J., Mackie, A. S., Ionescu-Ittu, R., Rahme, E. & Pilote, L. 2007. Congenital heart disease in the general population changing prevalence and age distribution. *Circulation*,115: 163-172.
- Mason, N. A., Springall, D. R., Burke, M., Pollock, J., Mikhail, G., Yacoub, M. H. & Polak, J. M. 1998. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. *J. Pathol.*,185: 313-318.
- McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H. & Rosenson, R. S. 2009. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc. ; and the Pulmonary Hypertension Association. *J. Am. Coll. Cardiol.*,53: 1573-1619.
- Mitchell, J. A., Ahmetaj-Shala, B., Kirkby, N. S., Wright, W. R., Mackenzie, L. S., Reed, D. M. & Mohamed, N. 2014. Role of prostacyclin in pulmonary hypertension. *Glob. Cardiol. Sci. Pract.*,2014 (4) : 382.
- Moodie, D. S. & Sterba, R. 2000. Long-term outcomes excellent for atrial septal defect repair in adults. *Cleve. Clin. J. Med.*,67: 591-597.
- Murphy, J. G., Gersh, B. J., McGoon, M. D., Mair, D. D., Porter, C. -b. J., Ilstrup, D. M., McGoon, D. C., Puga, F. J., Kirklin, J. W. & Danielson, G. K. 1990. Long-term outcome after surgical repair of isolated atrial septal defect: follow-up at 27 to 32 years. *N. Engl. J. Med.*,323: 1645-1650.
- Ozerol, I. H., Pac, F. A., Ozerol, E., Ege, E., Yologlu, S., Temel, I. & Pac, M. 2004. Plasma endothelin-1, homocysteine and serum nitric oxide values in patients with left-to-right shunt. *Indian Heart J.*,56: 653-657.

- Peacock, A., Murphy, N., McMurray, J., Caballero, L. & Stewart, S. 2007. An epidemiological study of pulmonary arterial hypertension. *Eur. Respir. J.*,30: 104-109.
- Pugh, M. E. and Hemnes, A. R.,2010. Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. *J. Womens Health*,6 (2), pp. 285-296.
- Rao, P. S. 2005. Diagnosis and management of acyanotic heart disease: Part II- left-to-right shunt lesions. *Indian J. Pediatr.*,72: 503-512.
- Roos-Hesselink, J., Meijboom, F., Spitaels, S., Van Domburg, R., Van Rijen, E., Utens, E., Bogers, A. & Simoons, M. 2003. Excellent survival and low incidence of arrhythmias, stroke and heart failure long-term after surgical ASD closure at young age. *Eur. Heart. J.*,24: 190-197.
- Rubin, L. J. 2012. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. *Life Sci.*,91: 517-521.
- Ruiz-Irastorza, G., Garmendia, M., Villar, I., Egurbide, M. V. and Aguirre, C.,2013. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. *Autoimmun. rev.*,12 (3), pp. 410-415.
- Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Sanchez, M. A. G., Kumar, R. K., Landzberg, M. & Machado, R. F. 2013. Updated clinical classification of pulmonary hypertension. *J. Am. Coll. Cardiol.*,62: D34-D41.
- Sitbon, O. & Morrell, N. 2012. Pathways in pulmonary arterial hypertension: the future is here. *Eur. Respir. Rev.*,21: 321-327.
- Sommer, R. J., Hijazi, Z. M. & Rhodes, J. F. 2008. Pathophysiology of Congenital Heart Disease in the Adult Part I: Shunt Lesions. *Circulation*,117: 1090-1099.
- Soubrier, F., Chung, W. K., Machado, R., Grünig, E., Aldred, M., Geraci, M., Loyd, J. E., Elliott, C. G., Trembath, R. C. & Newman, J. H. 2013. Genetics and genomics of pulmonary arterial hypertension. *J. Am. Coll. Cardiol.*,62.
- Stelzner, T., O'brien, R., Yanagisawa, M., Sakurai, T., Sato, K., Webb, S., Zamora, M., McMurtry, I. & Fisher, J. 1992. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. *Am. J. Physiol. Lung Cell. Mol. Physiol.*,262: L614-L620.
- Stewart, D. J., Levy, R. D., Cernacek, P. & Langleben, D. 1991. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? *Ann. Intern. Med.*,114: 464-469.
- Tuder, R. M., Cool, C. D., Geraci, M. W., Wang, J., Abman, S. H., Wright, L., Badesch, D. & Voelkel, N. F. 1999. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. *Am. J. Respir. Crit. Care Med.*,159: 1925-1932.
- Tutar, H. E., Imamoglu, A., Atalay, S., Gümüs, H. & Akar, N. 1999. Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension. *Int. J. Cardiol.*,70: 57-62.

- Tworetzky, W., Moore, P., Bekker, J. M., Bristow, J., Black, S. M. & Fineman, J. R. 2000. Pulmonary blood flow alters nitric oxide production in patients undergoing device closure of atrial septal defects. *J. Am. Coll. Cardiol.*,35: 463-467.
- Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M. & Evangelista, A. 2012. Guidelines on the management of valvular heart disease (version 2012). *Eur. Heart J.*,33: 2451-2496.
- Veyssier-Belot, C. & Cacoub, P. 1999. Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. *Cardiovasc. Res.*,44: 274-282.
- Vincent, J. A., Ross, R. D., Kassab, J., Hsu, J. M. & Pinsky, W. W. 1993. Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow. *Am. J. Cardiol.*,71: 1204-1207.
- Vogel, M., Berger, F., Kramer, A., Alexi-Meshkishvili, V. & Lange, P. 1999. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. *Heart*,82: 30-33.
- Vongpatanasin, W., Brickner, M. E., Hillis, L. D. & Lange, R. A. 1998. The Eisenmenger syndrome in adults. *Ann. Intern. Med.*,128: 745-755.
- Webb, G. & Gatzoulis, M. A. 2006. Atrial septal defects in the adult recent progress and overview. *Circulation*,114: 1645-1653.
- Yoshiyoshi, M., Nishioka, K., Nakao, K., Saito, Y., Matsumura, M., Ueda, T., Temma, S., Shirakami, G., Imura, H. & Mikawa, H. 1991. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. *Circulation*,84: 2280-2285.
- Zellers, T. M., McCormick, J., And Wu, Y.,1994. Interaction among ET-1, endothelium-derived nitric oxide, and prostacyclin in pulmonary arteries and veins. *Am J PhysiolHeart Circ Physiol*,267 (1), pp. H139-H147.
- Zen-Kong, D., Mian-Shin, T., Chee-Yin, C., Jun, C. & Jiunn-Ren, W. 2002. Effects of increased pulmonary flow on the expression of endothelial nitric oxide synthase and endothelin-1 in the rat. *Clin. Sci.*,103: 289S-293S.